Literature DB >> 25219510

Structural analysis of the human fibroblast growth factor receptor 4 kinase.

E Lesca1, A Lammens2, R Huber3, M Augustin2.   

Abstract

The family of fibroblast growth factor receptors (FGFRs) plays an important and well-characterized role in a variety of pathological disorders. FGFR4 is involved in myogenesis and muscle regeneration. Mutations affecting the kinase domain of FGFR4 may cause cancer, for example, breast cancer or rhabdomyosarcoma. Whereas FGFR1-FGFR3 have been structurally characterized, the structure of the FGFR4 kinase domain has not yet been reported. In this study, we present four structures of the kinase domain of FGFR4, in its apo-form and in complex with different types of small-molecule inhibitors. The two apo-FGFR4 kinase domain structures show an activation segment similar in conformation to an autoinhibitory segment observed in the hepatocyte growth factor receptor kinase but different from the known structures of other FGFR kinases. The structures of FGFR4 in complex with the type I inhibitor Dovitinib and the type II inhibitor Ponatinib reveal the molecular interactions with different types of kinase inhibitors and may assist in the design and development of FGFR4 inhibitors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dovitinib; Ponatinib; autoinhibition; rhabdomyosarcoma; tyrosine receptor kinase

Mesh:

Substances:

Year:  2014        PMID: 25219510     DOI: 10.1016/j.jmb.2014.09.004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.

Authors:  Meng-di Dai; Yue-Liang Wang; Jun Fan; Yang Dai; Yin-Chun Ji; Yi-Ming Sun; Xia Peng; Lan-Lan Li; Yu-Ming Wang; Wen-Hu Duan; Jian Ding; Jing Ai
Journal:  Acta Pharmacol Sin       Date:  2020-12-07       Impact factor: 7.169

3.  Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Authors:  Robin A Fairhurst; Thomas Knoepfel; Catherine Leblanc; Nicole Buschmann; Christoph Gaul; Jutta Blank; Inga Galuba; Jörg Trappe; Chao Zou; Johannes Voshol; Christine Genick; Peggy Brunet-Lefeuvre; Francis Bitsch; Diana Graus-Porta; Pascal Furet
Journal:  Medchemcomm       Date:  2017-06-08       Impact factor: 3.597

4.  The expression profiles of fibroblast growth factor 9 and its receptors in developing mice testes.

Authors:  Meng-Shao Lai; Chia-Yih Wang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Shaw-Jenq Tsai; Jih-Ing Chuang; Yung-Chia Chen; Bu-Miin Huang
Journal:  Organogenesis       Date:  2016-04-14       Impact factor: 2.500

5.  Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase.

Authors:  Tobias Klein; Navratna Vajpai; Jonathan J Phillips; Gareth Davies; Geoffrey A Holdgate; Chris Phillips; Julie A Tucker; Richard A Norman; Andrew D Scott; Daniel R Higazi; David Lowe; Gary S Thompson; Alexander L Breeze
Journal:  Nat Commun       Date:  2015-07-23       Impact factor: 14.919

6.  FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.

Authors:  S Pauliina Turunen; Pernilla von Nandelstadh; Tiina Öhman; Erika Gucciardo; Brinton Seashore-Ludlow; Beatriz Martins; Ville Rantanen; Huini Li; Katrin Höpfner; Päivi Östling; Markku Varjosalo; Kaisa Lehti
Journal:  Cell Death Differ       Date:  2019-03-22       Impact factor: 15.828

Review 7.  Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Authors:  Francesca Musumeci; Chiara Greco; Giancarlo Grossi; Alessio Molinari; Silvia Schenone
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639

Review 8.  Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting.

Authors:  Brendan Farrell; Alexander L Breeze
Journal:  Biochem Soc Trans       Date:  2018-12-13       Impact factor: 5.407

9.  Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

Authors:  Young K Chae; Fangxin Hong; Christos Vaklavas; Heather H Cheng; Peter Hammerman; Edith P Mitchell; James A Zwiebel; S Percy Ivy; Robert J Gray; Shuli Li; Lisa M McShane; Larry V Rubinstein; David Patton; P Mickey Williams; Stanley R Hamilton; Aaron Mansfield; Barbara A Conley; Carlos L Arteaga; Lyndsay N Harris; Peter J O'Dwyer; Alice P Chen; Keith T Flaherty
Journal:  J Clin Oncol       Date:  2020-05-28       Impact factor: 44.544

10.  Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.

Authors:  Daichao Wu; Ming Guo; Michael A Philips; Lingzhi Qu; Longying Jiang; Jun Li; Xiaojuan Chen; Zhuchu Chen; Lin Chen; Yongheng Chen
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.